# A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis

> **NCT03733925** · PHASE4 · COMPLETED · sponsor: **Johnson & Johnson Private Limited** · enrollment: 100 (actual)

## Conditions studied

- Spondylitis, Ankylosing
- Arthritis, Psoriatic

## Interventions

- **DRUG:** Golimumab

## Key facts

- **NCT ID:** NCT03733925
- **Lead sponsor:** Johnson & Johnson Private Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2021-11-15
- **Final completion:** 2021-11-15
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733925, "A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03733925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*